Summary

Cardiac Biomarkers Market Size, Share, and Analysis, By Type (Creatine Kinase-MB (CK-MB), Troponin, B-type Natriuretic Peptide (BNP), N-terminal Pro-BNP (NT-proBNP), and Others), By Application (Acute Coronary Syndrome, Myocardial Infarction, Congestive Heart Failure, and Others), By End User (Hospitals, Point of Care Testing, Laboratory Testing, Diagnostic Centers), By Region (North America, Europe, Asia-Pacific, and Rest of the World), And Regional Forecast 2024-2034

PRODUCT OVERVIEW
Cardiac Biomarkers Market is projected to exhibit a Compound Annual Growth Rate (CAGR) of 13.8% during the forecast span from 2024 to 2034. In 2023, the market size was assessed at USD 13.9 billion and is projected to reach USD 58.1 billion by the completion of 2034.
Cardiac biomarkers are compounds released into the bloodstream in response to heart damage or stress. They act as distress signals sent out by the heart. Various enzymes, hormones, and proteins, such as cardiac troponins and creatine kinase (CK), are examples of these biomarkers. Troponin is a key cardiac biomarker for detecting heart attacks, while CK-MB can also indicate heart damage. BNP is often used for diagnosing heart failure, and NT-proBNP serves a similar purpose in monitoring and diagnosing heart failure. These biomarkers play a crucial role in diagnosing heart attacks, assessing the severity of heart failure, tracking the effectiveness of treatments, and screening individuals at high risk. They offer advantages including early detection, high specificity and sensitivity, and treatment recommendations.

MARKET HIGHLIGHTS
Cardiac Biomarkers Market is expected to reach USD 58.1 billion during the forecast period. The rising prevalence of heart diseases globally is leading to a higher demand for diagnostic and monitoring tools like cardiac biomarkers. Additionally, with the world's population aging, there is a growing incidence of cardiovascular diseases, highlighting the importance of reliable diagnostic biomarkers. The market is also fueled by the growing understanding of the advantages of early detection and preventive care. Furthermore, the development of improved biomarker testing technologies that are more sensitive and faster is expected to drive market growth. Increased investment in cutting-edge diagnostic technology and personalized healthcare further contributes to the expansion of the market.
Cardiac Biomarkers Market Segments:

• By Type
o Creatine Kinase-MB (CK-MB)
o Troponin
o B-type Natriuretic Peptide (BNP)
o N-terminal Pro-BNP (NT-proBNP)
o Others
• By Application
o Acute Coronary Syndrome
o Myocardial Infarction
o Congestive Heart Failure
o Others
• By End User
o Hospitals
o Point of Care Testing
o Laboratory Testing
o Diagnostic Centers

MARKET DYNAMICS
Growth Drivers
Increasing Incidence of Heart Conditions are Critical to Boosting the Adoption of Cardiac Biomarkers
Advancements in Cardiac Biomarker Technologies Will Aid the Market
Restraint
High Costs of Cardiac Biomarker Tests Can Limit the Growth of the Cardiac Biomarkers Market

Key Players
• Abbott Laboratories
• Becton, Dickinson and Company
• Luminex Corporation
• Roche Diagnostics
• PerkinElmer, Inc.
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Fujirebio
• Beckman Coulter
• ACON Laboratories, Inc.
• Ortho Clinical Diagnostics
• Siemens Healthineers
• Randox Laboratories Ltd.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• Other Prominent Players (Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis)


Global Laboratory Temperature Control Units Market is further segmented by region into:
• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAG.R – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA


Reasons to Purchase this Report
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 3-month post-sales analyst support.

ページTOPに戻る

Table of Contents

1.Executive Summary
1.1. Regional Market Share
1.2.Business Trends
1.3. Cardiac Biomarkers Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1.Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4.Primary Research
2.5.Secondary Research
2.5.1.Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1.Market Definition
3.2.Cardiac Biomarkers Market: COVID-19 Impact
3.3. Key Segmentations
3.4.Key Developments
3.5.Allied Industry Data
4.Cardiac Biomarkers Market – Industry Insights
4.1. Industry Segmentation
4.2.COVID-19 overview of world economy
4.3.Industry Ecosystem Channel Analysis
4.4.Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1.Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4.Market Restraints
7.5. Market Trends
8.Risk Analysis
9. Market Analysis
9.1.Porter's Five Forces
9.2. PEST Analysis
9.2.1.Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10.Cardiac Biomarkers Market
10.1.Overview
10.2. Historical Analysis (2018-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Cardiac Biomarkers Market Size & Forecast 2024A-2034F
11.1. Overview
11.2.Key Findings
11.3.Market Segmentation
11.3.1.By Type
11.3.1.1. Creatine Kinase-MB (CK-MB)
11.3.1.1.1.By Value (USD Million) 2024A-2034F
11.3.1.1.2. Market Share (%) 2024A-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024A-2034F
11.3.1.2.Troponin
11.3.1.2.1. By Value (USD Million) 2024A-2034F
11.3.1.2.2.Market Share (%) 2024A-2034F
11.3.1.2.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.3.B-type Natriuretic Peptide (BNP)
11.3.1.3.1. By Value (USD Million) 2024A-2034F
11.3.1.3.2.Market Share (%) 2024A-2034F
11.3.1.3.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.4.N-terminal Pro-BNP (NT-proBNP)
11.3.1.4.1. By Value (USD Million) 2024A-2034F
11.3.1.4.2.Market Share (%) 2024A-2034F
11.3.1.4.3.Y-o-Y Growth (%) 2024A-2034F
11.3.1.5.Others
11.3.1.5.1. By Value (USD Million) 2024A-2034F
11.3.1.5.2.Market Share (%) 2024A-2034F
11.3.1.5.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2. By Application
11.3.2.1.Acute Coronary Syndrome
11.3.2.1.1. By Value (USD Million) 2024A-2034F
11.3.2.1.2.Market Share (%) 2024A-2034F
11.3.2.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.2.2. Myocardial Infarction
11.3.2.2.1.By Value (USD Million) 2024A-2034F
11.3.2.2.2. Market Share (%) 2024A-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.3. Congestive Heart Failure
11.3.2.3.1.By Value (USD Million) 2024A-2034F
11.3.2.3.2. Market Share (%) 2024A-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.2.4. Others
11.3.2.4.1.By Value (USD Million) 2024A-2034F
11.3.2.4.2. Market Share (%) 2024A-2034F
11.3.2.4.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.By End User
11.3.3.1.Hospitals
11.3.3.1.1. By Value (USD Million) 2024A-2034F
11.3.3.1.2.Market Share (%) 2024A-2034F
11.3.3.1.3.Y-o-Y Growth (%) 2024A-2034F
11.3.3.2. Point of Care Testing
11.3.3.2.1.By Value (USD Million) 2024A-2034F
11.3.3.2.2. Market Share (%) 2024A-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.3. Laboratory Testing
11.3.3.3.1.By Value (USD Million) 2024A-2034F
11.3.3.3.2. Market Share (%) 2024A-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024A-2034F
11.3.3.4. Diagnostic Centers
11.3.3.4.1.By Value (USD Million) 2024A-2034F
11.3.3.4.2. Market Share (%) 2024A-2034F
11.3.3.4.3. Y-o-Y Growth (%) 2024A-2034F
12.North America Cardiac Biomarkers Market Size & Forecast 2024A-2034F
12.1.Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1.By Type
12.3.2. By Application
12.3.3. By End User
12.4. Country
12.4.1. United States
12.4.2. Canada
13.Europe Cardiac Biomarkers Market Size & Forecast 2024A-2034F
13.1.Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1.By Type
13.3.2. By Application
13.3.3. By End User
13.4.Country
13.4.1.Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14.Asia-Pacific Cardiac Biomarkers Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3.Market Segmentation
14.3.1.By Type
14.3.2. By Application
14.3.3. By End User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4.Japan
14.4.5.Rest of APAC
15.Middle East and Africa Cardiac Biomarkers Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1.By Type
15.3.2. By Application
15.3.3. By End User
15.4.Country
15.4.1.Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4.South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Cardiac Biomarkers Market Size & Forecast 2024A-2034F
16.1.Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1.By Type
16.3.2. By Application
16.3.3. By End User
16.4. Country
16.4.1.Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1.Company market share, 2023
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Abbott Laboratories
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2.Key Clients
18.1.4.3.Market Share
18.1.4.4.Recent News & Development (Last 3 Yrs.)
18.2. Becton, Dickinson and Company
18.3. Luminex Corporation
18.4. Roche Diagnostics
18.5. PerkinElmer, Inc.
18.6. Bio-Rad Laboratories, Inc.
18.7. bioMérieux SA
18.8. Fujirebio
18.9. Beckman Coulter
18.10.ACON Laboratories, Inc.
18.11.Ortho Clinical Diagnostics
18.12. Siemens Healthineers
18.13. Randox Laboratories Ltd.
18.14.Trinity Biotech
18.15. Thermo Fisher Scientific Inc.
18.16. Other Prominent Players
19. Appendix
20.Consultant Recommendation